Die Suchmaschine für Unternehmensdaten in Europa
UK-Förderung (1.786.575 £): KAT2A PROTACs zur Differenzierung von Blasten und leukämischen Stammzellen zur Behandlung der akuten myeloischen Leukämie Ukri01.01.2024 Forschung und Innovation im Vereinigten Königreich, Großbritannien
Auf einen Blick
Text
KAT2A PROTACs zur Differenzierung von Blasten und leukämischen Stammzellen zur Behandlung der akuten myeloischen Leukämie
| Zusammenfassung | Acute Myeloid Leukaemia (AML) is a form of cancer that starts in the bone marrow and moves into the blood. The loss of blood cells to fight infection and to mediate blood clotting frequently leads to sepsis or significant hemorrhage. This cancer is most common in the older population (over 65 years) and is difficult to treat. Current therapies are relatively crude chemotherapeutic "sledgehammers" and are not widely effective and/or are poorly tolerated, particularly by the elderly. This leads to over 70% of patients over 65 years old dying within the first year of diagnosis and fewer than 15% living beyond year 5. The Medicines Discovery Institute at Cardiff University has developed a novel therapeutic agent which can revolutionise treatment of this disease and treat all AML patients, with the potential to be well tolerated in the vulnerable elderly population. We will do this by targeting a specific protein in the body, known as KAT2A, which plays a key role in blocking the body from recognising and destroying the cancer cells. Our approach has exploited a novel technology that allows us to harness the body's own molecular waste disposal systems within the cell to remove this target protein. This solution was unimaginable 5 years ago, but now presents us with the opportunity to advance a technology solution that could be widely used and would be less toxic than current treatments. Our project has many years of discovery effort behind it, and has completed an extensive campaign of optimisation and characterisation to identify three advanced molecules which have the potential to progress into clinical trials. Now, we need to further study these molecules to complete the data package that is required by regulatory agencies and to select the best of these molecules as the potential new therapy. These studies will establish the best dose to use for our novel molecules and inform us on how best to use these molecules to help patients. These experiments significantly enhance the potential for onward investment by groups focused on the development of new cancer treatments for this patient population. |
| Kategorie | Research Grant |
| Referenz | MR/X029557/1 |
| Status | Closed |
| Laufzeit von | 01.01.2024 |
| Laufzeit bis | 31.10.2025 |
| Fördersumme | 1.786.575,00 £ |
| Quelle | https://gtr.ukri.org/projects?ref=MR%2FX029557%2F1 |
Beteiligte Organisationen
| CARDIFF UNIVERSITY |
Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Cardiff University, Cardiff, Großbritannien.
